Press Releases

November 13, 2024

TAE Life Sciences and Stella Pharma Announce Strategic Agreement for Development and Commercialization of BPA for BNCT Cancer Therapy in the USA and Europe

November 13, 2024 — Irvine, CA – TAE Life Sciences (TLS), a leader in developing boron neutron capture therapy (BNCT) technology and associated innovative boron target drugs, and Stella Pharma, the pioneering developer of boronophenylalanine (BPA) under the product name, Steboronine®, for BNCT, are pleased to announce a strategic collaboration focused on the development, commercialization and expansion of BNCT using BPA in the United States and European markets.

Stella Pharma’s BPA drug is the world’s first and only clinically approved boron drug for BNCT, marking a breakthrough in cancer treatment. Japan became the first country to approve BNCT for the treatment of head and neck cancers, using Stella Pharma’s pioneering BPA drug. Now, Stella Pharma, as the leading producer and supplier of BPA, has joined forces with TAE Life Sciences to expand the adoption of BNCT worldwide.

Supporting the Future of BNCT Therapy

The collaboration objectives include extensive international cooperation in the development and commercialization of BNCT and BPA across the USA and Europe with clinical trials anticipated to begin in 2026. TLS will serve as the exclusive commercial partner for Stella Pharma’s BPA in these regions, representing a significant expansion of BNCT accessibility outside of Asia.

“Our partnership with Stella Pharma combines our shared commitment to advancing BNCT as a viable cancer treatment for patients worldwide,” said Rob Hill, CEO of TAE Life Sciences. “We are excited to bring the proven benefits of BPA to U.S. and European healthcare institutions and to support BNCT globally with this powerful therapeutic solution.”

Both companies have also committed to supporting BNCT equipment vendors across all markets in implementing BPA-based BNCT treatments. By fostering partnerships within the BNCT ecosystem, TLS and Stella Pharma aim to enhance the clinical reach of BNCT in treating recurrent head and neck cancers and advancing clinical studies for other cancers, including brain, skin, breast, esophagus, and lung cancers.

“Our alliance with TAE Life Sciences marks a significant step in expanding the reach of BPA-based BNCT treatments beyond Asia,” said Koki Uehara, President and Chief Operating Officer of Stella Pharma. “We look forward to collaborating internationally to develop and commercialize BNCT and aim to deliver this advancing cancer treatments to patients and their families worldwide.”

Exploring Future Opportunities Together

Stella Pharma and TAE Life Sciences share a vision of advancing BNCT treatment for hard-to-treat cancers and pledge to explore additional areas for collaboration. Through this alliance, they seek to accelerate innovation, expand treatment options, and ultimately improve outcomes for cancer patients worldwide.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam™ BNCT system and proprietary boronated drugs are still in the investigational stage, and not available commercially. More information about TAE Life Sciences is available at taelifesciences.com.

June 4, 2024

TAE Life Sciences Appoints Commercial Leadership Team and Announces Distribution Deal with Radiosurgery Global

Committed to Driving the Adoption of Boron Neutron Capture Therapy for Cancer, TAE Life Sciences Bolsters Resources to Expand the Number of Alphabeam Clinical Installations Worldwide

IRVINE, Calif., June 4, 2024 – TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the formation of its new commercial leadership team, dedicated to driving the company’s expansion across the Americas, APAC (Asia-Pacific) and EMEAI (Europe, Middle East, Africa, and India). With extensive experience and expertise with their respective markets, each member of this team will serve as the general manager for their region. With a focused goal of expanding the company’s global footprint, the commercial leadership team is poised to enhance market reach, foster strategic partnerships, and ultimately expand the number of Alphabeam BNCT installations at clinical sites worldwide.

TAE Life Sciences’ commercial leadership team members:

Anna Theriault, GM for the Americas, and Global VP of Marketing: A tenured radiation oncology business and marketing executive, Anna brings a wealth of experience in driving adoption in evolving radiation therapy, data, and oncology solutions from previous senior leadership roles at Accuray and Elekta.
Michael Sandhu, GM for Europe, the Middle East, Africa, and India: With over 30 years of experience in radiation therapy, Michael founded remediumRT AG and held key roles at Varian Medical Systems. He specializes in emerging market growth and government negotiations.
Peter Stafford, GM for Asia Pacific: With over 15 years of experience in radiation oncology and biopharmaceuticals, Peter has held key technical and business roles at Accuray and Pharmaceutical Product Development, Inc.

In a strategic move to bolster its presence in India, TAE Life Sciences is excited to announce Radiosurgery Global (RSG) as its new distribution partner for the country. RSG excels in providing comprehensive support through a network of skilled consultants, partners, and advisors specializing in sales channels, project management, construction, digital and print marketing, investment advisory, engineering, service, and financing.

“TAE Life Sciences’ innovative Alphabeam BNCT system has the potential to revolutionize cancer care with its unparalleled treatment accuracy. We are excited to combine their cutting-edge solutions with our established radiation oncology distribution infrastructure and sales network to advance the field of radiation oncology in India,” said Kapil Kalra, Managing Director, Radiosurgery Global.

Working with RSG will help TAE Life Sciences to strategically target both seasoned professionals in radiation oncology as well as the institutions adopting the latest cancer care innovations in India. With RSG’s proven expertise and extensive experience, this partnership is set to significantly enhance TAE Life
Sciences’ reach and growth in a key market.

“At TAE Life Sciences, our mission is to make transformative advancements in cancer treatment accessible worldwide. The appointment of our new commercial leadership team and expansion of our distribution partners are pivotal steps toward realizing this vision,” said Rob Hill, CEO, TAE Life Sciences.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

April 3, 2024

TAE Life Sciences’ Neutron Beam System Receives Acceptance Enabling the Start of BNCT Clinical Trials in China

A Key Component of Neuboron’s NeuPex AB-BNCT System, TAE Life Sciences’ Neutron Beam System Receives Performance Acceptance and Passes Class III Registration Inspection

IRVINE, Calif., April 3, 2024 – TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the successful completion of acceptance testing and regulatory registration inspection of its accelerator- based neutron beam system (NBS), marking a significant milestone in BNCT global market adoption. Developed and manufactured in the United States, TAE Life Sciences’ NBS has met all specifications outlined by Neuboron Medical and the local regulatory body, enabling human BNCT clinical trials to begin this month in China.

The completion of acceptance testing underscores TAE Life Sciences’ commitment to international safety and efficacy standards, making it the first US company to have its system achieve such recognition. This major technological progress demonstrates how TAE Life Sciences has solidified its leading position in the growing field of BNCT. As the company progresses in establishing Alphabeam BNCT sites worldwide, collaborating with Neuboron to provide them with a Neutron Beam System has paved a distinctive pathway into the Chinese market.

“We worked closely with Neuboron to ensure our accelerator-based NBS precisely delivered the results required for BNCT and are thrilled to have successfully completed acceptance testing and regulatory inspection,” stated Rob Hill, CEO at TAE Life Sciences. “This milestone not only demonstrates our dedication to delivering cutting-edge cancer treatment solutions, but also signifies our ability to meet rigorous international standards.”

Additionally, the Beijing Institute of Medical Device Testing has completed registration testing of the full Neuboron Medical’s NeuPex AB-BNCT system, which includes TAE Life Science’s NBS. This milestone marks a significant regulatory approval step, enabling Neuboron to move forward with clinical trials in China. Neuboron will commence clinical trials at Xiamen Humanity Hospital.

The latest market analysis report by Intel Market Research forecasts robust growth in the BNCT market, with global revenues projected to reach $2.2 billion by 2030. TAE Life Sciences, alongside industry leaders such as Neuboron, Sumitomo, and others, is poised to play a pivotal role in driving this exponential growth.

As the BNCT market continues to expand, TAE Life Sciences remains at the forefront of innovation, delivering transformative solutions to cancer patients worldwide.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

For more information about Neuboron and its technologies, please visit neuboron.com/.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.

March 13, 2024

TAE Life Sciences Awarded Patent for Borylated Amino Acid Compositions for Boron Neutron Capture Therapy

The Granted Patent Covers the Compositions of BTS And BTS(OMe) And Novel Methods Of
Their Production

Irvine, Calif., November 7, 2024 – TAE Life Sciences, a leading innovator in cancer treatment technologies, today announced that the United States Patent and Trademark Office (USPTO) has granted the company’s U.S. Patent No. US 11,884,688 B2, for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT). This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant
milestone in the field of radiation therapy.

Boron Neutron Capture Therapy (BNCT) is a promising approach for the treatment of cancer and other diseases, utilizing boron-containing compounds to selectively deliver radiation to tumor cells while sparing healthy tissue. TAE Life Sciences' patented borylated amino acid compounds, BTS and BTS(OMe), may offer an effective means of enhancing efficacy of BNCT, potentially opening new avenues for targeted treatments for cancer and immunological disorders.

“This patent represents a significant milestone for TAE Life Sciences, validating the innovative work of our research and development teams. We are excited about the potential impact of BTS and BTS(OMe) in advancing BNCT cancer treatment and improving patient outcomes.” Rob Hill, CEO at TAE Life Sciences.

The patent covers not only the compositions of BTS and BTS(OMe) but also novel methods of their production, enabling scalable manufacturing processes to meet the growing demand for BNCT agents. With this patent, TAE Life Sciences solidifies its position as a leader in radiation therapy innovation, poised to transform the landscape of cancer treatment.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.

November 8, 2023

TAE Life Sciences Earns Oncology Innovation of the Year Award

Earning the BioTech Breakthrough Award for Oncology Innovation of the Year validates the progress TAE Life Sciences has made in readying its Alphabeam BNCT system for clinical trials worldwide

Irvine, Calif., November 8, 2023 – TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year. This prestigious accolade acknowledges TAE Life Sciences' pioneering work in radiation oncology and highlights the role its innovative Alphabeam™ Neutron System and proprietary boronated drugs are playing in making Boron Neutron Capture Therapy (BNCT) a mainstay of modern oncology.

“The advancements we’ve made hold the potential to be applied across a broader range of clinical scenarios, expanding the horizons of BNCT as a next-generation cancer treatment,” said TAE Life Sciences' CEO, Rob Hill. “Thank you to BioTech Breakthrough for validating our work. With our BNCT approach, empowered by Alphabeam and boronated drugs, we are leading the way to faster, more effective, and safer treatment options for a range of difficult-to-treat cancers that is sure to enhance patient outcomes and save lives.”

The Biotech Breakthrough Award symbolizes our commitment to shaping the future of cancer treatment. TAE Life Sciences' Alphabeam Neutron System generates high-intensity, precision-focused, low-energy neutrons, revolutionizing BNCT. This innovative approach provides highly targeted cancer treatment with minimal collateral damage, reducing the impact on healthy tissue.

At the core of this achievement is Alphabeam's capacity to deliver thermal neutrons, enabling the interaction between boron-10 and tumor cells. This interaction results in the release of high-energy alpha particles and lithium nuclei, destroying tumor cell DNA and ultimately killing the cancer cells while sparing surrounding healthy tissue. This groundbreaking technology not only holds promise for head and neck cancers but also eliminates the need for dangerous nuclear reactors, making it a safer, cost effective, and versatile alternative for cancer treatment.

“TAE Life Sciences is spearheading pivotal advancement in biotech. By combining the precision of Alphabeam with the selectivity of their boronated drugs, the company is setting the stage for a paradigm shift in cancer therapy,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “Historically, BNCT required a nuclear reactor as a neutron source, which is extremely expensive and impractical for hospitals to adopt and maintain. TAE’s Alphabeam system eliminates this need and offers flexibility for various clinical settings. This versatility, coupled with its potential to treat various types of cancers, grants TAE our ‘Oncology Innovation of the Year’ award.”

Complementing Alphabeam is TAE Life Sciences' proprietary boronated drug, TC220, which offers numerous advantages over conventional boronophenylalanine (BPA). Pre-clinical studies have shown TC220's superior ability to deliver boron effectively to tumor cells, expanding the horizons of BNCT as a next-generation cancer treatment.

The Alphabeam system's versatility enhances its market potential, as it can be integrated into existing medical infrastructures and offers the promise of reducing cancer treatment costs. This groundbreaking technology is being deployed to cancer hospitals worldwide, signaling a transformative shift in oncology.

TAE Life Sciences is committed to advancing the frontiers of oncology through innovation and patientfocused care. This award is a testament to the company's dedication to making a profound and positive impact in biotechnology.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.

September 28, 2023

TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting

San Diego And Irvine, CA – September 28, 2023 – TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, is thrilled to announce it is bringing BNCT to this year's annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The company is set to revolutionize the way attendees perceive BNCT with an immersive Augmented Reality (AR) experience that offers an in-depth look at the future of cancer treatments, informative talks about the state of BNCT, and a variety of captivating exhibits.
TAE Life Sciences Brings BNCT to ASTRO
The AR experience at the TAE Life Sciences booth will offer visitors a captivating journey into the world of BNCT, featuring:

A virtual tour of the Alphabeam™ system, showcasing the clinical workflow of BNCT and illustrating the inner workings of this revolutionary technology.
Insights into the setup of a BNCT system, including details on building requirements, layout, and the treatment process.

“We’re on the verge of redefining how the world treats cancer and ASTRO is the perfect venue to showcase the capabilities of our Alphabeam BNCT system. We're not just showing a glimpse of our technology at the show; we're sharing a vision for a future where cancer is treated with unprecedented precision. We hope that the immersive experience we’re bringing to the show ignites a spark of hope in the hearts of attendees, and together, we can work towards a brighter future for cancer patients,” said Rob Hill, CEO at TAE Life Sciences.

TAE Life Sciences will host a presentation, titled “Reimagining BNCT for Biologically Targeted Radiation Therapy,” at its booth stage on October 1 at 11:00 AM. Featuring talks from Rob Hill, CEO of TAE Life Sciences, Minesh Mehta, MD, from Miami Cancer Institute, and Sandro Rossi, General Manager and Technical Director at CNAO, this presentation will include updates on the global progress of BNCT, preclinical and clinical results, and insight into the treatment’s profound significance in shaping the future of cancer treatment.

Presentation Details:

Who: Robert Hill, CEO at TAE Life Sciences; Minesh Mehta, Chief of Radiation Oncology at Miami Cancer Institute; Sandro Rossi, General Manager at CNAO
What: Presentation: Reimagining BNCT for Biologically Targeted Radiation Therapy
When: October 1, 2023 at 11:00 AM
Where: San Diego Convention Center, Booth 3732

Sandro Rossi from CNAO shared his enthusiasm, stating, “Our collaboration with TAE Life Sciences marks a significant step forward in BNCT and brings an exciting addition to Europe's first Hadrontherapy center. By incorporating BNCT into our comprehensive treatment offerings, we are expanding the horizons of radiation therapy to treat metastatic cancers. This groundbreaking approach has the potential to redefine how we combat cancer, making treatments more effective and tailored to each patient's unique needs. Together with TAE Life Sciences, we are not just advancing technology; we are advancing the future of cancer care in Europe and beyond.”

At ASTRO, TAE Life Sciences will have several exciting exhibits on display in its booth, including:

BNCT treatment planning demonstration featuring TAE Life Sciences’ proprietary dose engine running on the Raysearch treatment planning engine.
Details about TAE Life Sciences' innovative BNCT drug development program, showcasing the latest advancements in its antibody boron conjugate (ABC) drugs as well as pre-clinical data.
A compelling poster comparing treatment planning outcomes with TAE Life Sciences' Boronotyrosine (BTS) drug versus Boronophenylalanine (BPA), shedding light on the significant advantages of BTS in boron delivery for BNCT interventions.

Minesh Mehta, representing Miami Cancer Institute, passionately emphasized the importance of accelerating BNCT research in the United States, stating, “Collaborations like the one between TAE Life Sciences and CNAO are essential to advancing cancer care. The opportunity for BNCT is burgeoning, especially with the increasing availability of antibody-drug conjugates (ADCs). Currently, there are a dozen or more ADCs that can be harnessed for boron conjugation. Fast-tracking BNCT research in the USA is not just a priority; it's an urgent necessity. We must seize this moment to bring BNCT to the forefront of modern cancer treatment and offer new hope to patients across the nation and beyond.”

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.

Andrea Monti Hughes, PhD presented at 61st Annual PTCOG Conferences, in vivo experimental testing data of novel boronated mediated Boron Neutron Capture Therapy

Madrid and Irvine, Calif., July 06, 2023 – TAE Life Sciences, a pioneering company in the field of cancer treatment, today announces the results from early testing of its TC440 boron-containing dipeptide compound for Boron Neutron Capture Therapy (BNCT). The findings suggest that TC440, along with its counterpart TC442, holds promise in revolutionizing cancer treatment strategies.

"Finding safe and effective ways to treat a variety of cancers is of utmost importance in our mission to improve and transform cancer care. The work we are doing at TAE Life Sciences to create new drugs like TC440 for BNCT is critical in this endeavor,” said Kendall Morrison, Chief Science Officer, TAE Life Sciences. “The promising preliminary results from our early testing indicate that these exciting new peptides hold significant potential in revolutionizing cancer treatment strategies. These findings highlight the immense potential of TC440 in enhancing the therapeutic efficacy of BNCT, bringing us closer to a future where safer and more effective treatments are available for cancer patients.”

TC440 and TC442 belong to a family of dipeptides that were synthesized at TAE Life Sciences using cuttingedge BPA Structural Analysis Relationship (SAR) chemistry. These compounds have demonstrated superior solubility compared to the widely used Boronophenylalanine (BPA), enabling the formulation of highly concentrated solutions. Formulations of TC440 and TC442 in fructose at 150 mg/ml have been achieved, providing a remarkable advancement in delivering boron to tumors. By leveraging the dipeptides' improved solubility, higher tumor boron delivery was achieved in multiple xenograft models, showcasing the superior uptake of TC440 and TC442. In addition to enhanced solubility, TC440 and TC442 possess the ability to be internalized via LAT1 transporters and PEPT1, even in LAT1 negative cell lines.

One of the most exciting discoveries is that these compounds deliver two to three times more boron than BPA in multiple human xenograft models and have a longer half-life compared to BPA. This increased boron delivery capability and longer half-life hold immense potential in enhancing the therapeutic efficacy of BNCT as a treatment modality.

To further investigate the therapeutic applications of TC440 and TC442, TAE Life Sciences is collaborating on BNCT experiments with the Department of Radiobiology at the National Atomic Energy Commission (CNEA) with Dr. Andrea Monti Hughes and Team, from Argentina. Initial studies conducted in the hamster cheek pouch oral cancer model have yielded encouraging preliminary results and were presented at 61st Annual PTCOG Conferences held in Spain, this year.

The ongoing study conducted in the hamster cheek pouch oral cancer model, which closely mimics the development of precancer and malignant human oral tumors, is a critical milestone in the research journey. The model provides a unique tumor environment surrounded by precancerous tissue, allowing researchers to investigate BNCT's dose-limiting effects, as observed in field-cancerized oral mucosa in head and neck cancer patients.

In this preliminary study, an 800 mg TC440/kg dose has demonstrated an increase in boron uptake compared to the 300 mg BPA/kg dose typically administered during testing, while maintaining higher tumor/blood and tumor/normal tissue ratios. However, similar boron concentrations and ratios were achieved compared to 800 mg BPA/kg. Unlike the BPA solution, the TC440 formulation exhibited no precipitation issues, providing a practical advantage.

When evaluating the therapeutic effect of BPA/BNCT versus TC440/BNCT, the preliminary study unveiled promising results. TC440 demonstrated a doubling of complete responses compared to BPA/BNCT protocols, particularly in medium and large hamster tumors treated with TAE/BNCT. Additionally, partially responded tumors treated with TC440 that exhibited a 50% in volume reduction were higher than in the BPA/BNCT group. Ongoing studies to confirm these early findings are underway.

Ongoing studies will further explore the potential of new dipeptides from TAE Life Sciences and expand upon these exciting preliminary findings. “The study of new boron compounds that could increase significantly BNCT therapeutic effect while preserving dose-limiting tissues is of utmost importance in BNCT. Huge efforts have been done for many years around the World, and radiobiological studies in in vivo models are a critical step to decide if a boron compound could be consider potentially useful in a clinical setting” said Andrea Monti Hughes (CNEA/CONICET, Argentina).

The groundbreaking discovery of TC440 and its therapeutic potential for cancer treatment using BNCT marks a significant milestone in the field of oncology. The company will continue to investigate the therapeutic potential of its TC440 and TC442 boron-containing drugs and will have the results published in a peer-reviewed scientific journal.

TAE Life Sciences is committed to advancing innovative solutions to address the challenges of cancer treatment, with the goal of improving patient outcomes and transforming the future of cancer care. Morrison will be presenting the results of this collaborative study with CNEA at the 19th Annual Japanese Neutron Capture Therapy Congress in Kyoto, Japan.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

About BNCT
BNCT is a combination treatment based on the reaction that occurs when a non-toxic compound containing boron-10 is irradiated with a low-energy neutron beam. BNCT differs radically from other radiation therapies and shows promise in becoming the next-generation cancer treatment. Research has shown that BNCT has the capability of killing cancer cells that are resistant to traditional radiation therapy with limited harm to healthy tissue. Current advances in both neutron radiation technology and medicinal boron drug targeting are enabling BNCT’s potential to improve patient care while also improving treatment economics. To date, approximately 2,000 patients have been treated with BNCT at research sites worldwide.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.